- The report contains detailed information about Marina Biotech, Inc. that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
- Another part of the report is a SWOT-analysis carried out for Marina Biotech, Inc.. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company’s strengths, weaknesses, opportunities, and possible threats against it.
- The Marina Biotech, Inc. financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company’s long-term solvency. This sort of company's information will assist and strengthen your company’s decision-making processes.
- In the part that describes Marina Biotech, Inc. competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company’s competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company’s business and sales activities will be boosted by gaining an insight into your competitors’ businesses.
- Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of Marina Biotech, Inc. business.
About Marina Biotech, Inc.
Marina Biotech, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of pharmaceuticals based on RNA interference (RNAi).
The company operates in the areas of RNAi, molecular and cellular biology, lipid, oligonucleotide and peptide chemistry, pharmacology and bioinformatics necessary to discover and develop modified RNAi-based compounds designed to elicit specific therapeutic effects on a target-by-target basis. The company in-licenses and further develops RNAi- and delivery-related technologies, forming a single integrated drug discovery platform.
The company is developing technologies and therapeutics based on the RNAi. It has created a drug discovery platform, which combines novel and proprietary siRNA constructs with novel and proprietary siRNA delivery technologies, to develop RNAi-based therapeutics for the treatment of human diseases.
RNAi Drug Discovery Platform: The company is making advances in both areas crucial to the development of RNAi-based therapeutics: siRNA constructs and siRNA delivery.
siRNA Constructs: The companys siRNA constructs include substitution chemistry (Unlocked Nucleobase Analogs (UNAs), and a three-stranded construct (Meroduplex).
Delivery: The company's delivery platform utilizes liposomal delivery technology and incorporates a proprietary molecule called DiLA2 (Di-Alkylated Amino Acid). In addition, it is using peptides for both the formation of stable siRNA nanoparticles, as well as targeting moieties for siRNA molecules.
RNAi Partnering and Licensing Agreements
Roche: In February 2009, the company entered into an agreement with F. Hoffmann-La Roche Inc., a New Jersey corporation, and F. Hoffmann-La Roche Ltd., a Swiss corporation (collectively, Roche), pursuant to which it granted to Roche a worldwide license to a portion of its technology platform, for the development of RNAi-based therapeutics.
Novartis: In March 2009, the company entered into an agreement with Novartis Institutes for BioMedical Research, Inc. (Novartis), pursuant to which it granted to Novartis a worldwide license to its DiLA2-based siRNA delivery platform.
University of Michigan: The company has entered into a license agreement to IP from the University of Michigan covering cationic peptides for enhanced delivery of nucleic acids. It is using these peptides to create siRNA nanoparticles to improve mRNA knockdown. The company sublicensed this IP to Novartis on a nonexclusive basis in March 2009.
The company's primary biotechnology competitor in the RNAi field is Alnylam Pharmaceuticals, Inc. Its other smaller biotechnology companies in the space include Calando Pharmaceuticals; Cequent Pharmaceuticals; Dicerna Pharmaceuticals, Inc.; Novosom AG; Quark Pharmaceuticals, Inc.; RXi Pharmaceuticals Corporation; Santaris Pharma A/S; Silence Therapeutics plc; Tacere Therapeutics, Inc.; and Tekmira Pharmaceutical Corp. In addition to biotechnology companies, it competes with international pharmaceutical companies with internal RNAi R&D programs, including AstraZeneca, GlaxoSmithKline plc, Merck & Co., Novartis, Pfizer, Inc., and Roche.
The company was founded in 1983. It was formerly known as Marina Biotech, Inc. and changed its name to Marina Biotech, Inc. on July 22, 2010.
The above Company Fundamental Report is a half-ready report and contents are subject to change.
It means that we have all necessary data in our database to prepare the report but need 2-3 days to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.
1. MARINA BIOTECH, INC. COMPANY PROFILE
1.2. Financial Performance
1.3. Key Executives
1.4. Ownership and Major Holders
1.5. Company History
2. MARINA BIOTECH, INC. BUSINESS OVERVIEW
2.2. Major Products and Services
2.3. Markets and Sales Activities
2.4. Locations, Subsidiaries, Operating Units
3. MARINA BIOTECH, INC. SWOT ANALYSIS
4. MARINA BIOTECH, INC. FINANCIAL ANALYSIS
4.1.1. Income Statement
4.1.2. Balance Sheet
4.1.3. Cash Flow
4.2. Financial Ratios
4.2.2. Margin Analysis
4.2.3. Asset Turnover
4.2.4. Credit Ratios
4.2.5. Long-Term Solvency
4.2.6. Growth Over Prior Year
4.2.7. Financial Ratios Charts
4.3. Stock Market Snapshot
5. MARINA BIOTECH, INC. COMPETITORS AND INDUSTRY ANALYSIS
5.1. Marina Biotech, Inc. Direct Competitors
5.2. Comparison of Marina Biotech, Inc. and Direct Competitors Financial Ratios
5.3. Comparison of Marina Biotech, Inc. and Direct Competitors Stock Charts
5.4. Marina Biotech, Inc. Industry Analysis
5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
5.4.2. Marina Biotech, Inc. Industry Position Analysis
6. MARINA BIOTECH, INC. NEWS & EVENTS
6.1. News & PR Activity Analysis
6.2. IR Corporate News
6.3. Marketing News
6.4. Corporate Events
7. MARINA BIOTECH, INC. EXPERTS REVIEW1
7.1. Experts Opinion
7.2. Experts Estimates
8. MARINA BIOTECH, INC. ENHANCED SWOT ANALYSIS2
9. UNITED STATES PESTEL ANALYSIS2
9.2. Economic Factors
9.3. Social Factors
9.4. Technological Factors
9.5. Environmental Factors
9.6. Legal Factors
10. MARINA BIOTECH, INC. IFE, EFE, IE MATRICES2
10.2. External Factor Evaluation Matrix
10.3. Internal External Matrix
11. MARINA BIOTECH, INC. PORTER FIVE FORCES ANALYSIS2
12. MARINA BIOTECH, INC. VRIO ANALYSIS2
APPENDIX: RATIO DEFINITIONS
LIST OF TABLES
Marina Biotech, Inc. Key Facts
Income Statement Key Figures
Balance Sheet Key Figures
Cash Flow Statement Key Figures
Financial Performance Abbreviation Guide
Marina Biotech, Inc. Key Executives
Key Executives Biographies1
Key Executives Compensations1
Marina Biotech, Inc. Major Shareholders
Marina Biotech, Inc. History
Marina Biotech, Inc. Products
Revenues by Segment
Revenues by Region
Marina Biotech, Inc. Offices and Representations
Marina Biotech, Inc. SWOT Analysis
Yearly Income Statement Including Trends
Income Statement Latest 4 Quarters Including Trends
Yearly Balance Sheet Including Trends
Balance Sheet Latest 4 Quarters Including Trends
Yearly Cash Flow Including Trends
Cash Flow Latest 4 Quarters Including Trends
Marina Biotech, Inc. Profitability Ratios
Margin Analysis Ratios
Asset Turnover Ratios
Long-Term Solvency Ratios
Financial Ratios Growth Over Prior Year
Marina Biotech, Inc. Capital Market Snapshot
Marina Biotech, Inc. Direct Competitors Key Facts
Direct Competitors Profitability Ratios
Direct Competitors Margin Analysis Ratios
Direct Competitors Asset Turnover Ratios
Direct Competitors Credit Ratios
Direct Competitors Long-Term Solvency Ratios
Pharmaceuticals and Biotechnology Industry Statistics
Marina Biotech, Inc. Industry Position
Company vs. Industry Income Statement Analysis
Company vs. Industry Balance Sheet Analysis
Company vs. Industry Cash Flow Analysis
Company vs. Industry Ratios Comparison
Marina Biotech, Inc. Consensus Recommendations1
Analyst Recommendation Summary1
Price Target Summary1
Experts Recommendation Trends1
Revenue Estimates Analysis1
Earnings Estimates Analysis1
Revenue Estimates Trend1
Earnings Estimates Trend1
LIST OF FIGURES
Marina Biotech, Inc. Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit
Profit Margin Chart
Operating Margin Chart
Return on Equity (ROE) Chart
Return on Assets (ROA) Chart
Debt to Equity Chart
Current Ratio Chart
Marina Biotech, Inc. 1-year Stock Charts
Marina Biotech, Inc. 5-year Stock Charts
Marina Biotech, Inc. vs. Main Indexes 1-year Stock Chart
Marina Biotech, Inc. vs. Direct Competitors 1-year Stock Charts
Marina Biotech, Inc. Article Density Chart
2 – These sections are available only when you purchase a report with appropriate additional types of analyses.
The complete financial data is available for publicly traded companies.
Enhanced SWOT Analysis
- How to use the strengths to take advantage of the opportunities?
- How to use the strengths to reduce likelihood and impact of the threats?
- How to overcome the weaknesses that obstruct taking advantage of the opportunities?
- How to overcome the weaknesses that can make the threats a reality?
Key Factors Examined by PESTEL Analysis:
- Legal – What laws and legislation will exert influence on the style the business is carried out?
IFE, EFE, IE Matrices
Porter Five Forces Analysis
- What composes a threat of substitute products and services?
- Is there a threat of new competitors entering the market?
- What is the intensity of competitive rivalry?
- How big is the bargaining power of buyers?
- How significant is the bargaining power of suppliers?
- Tangible resources
- Intangible resources
- Innovation and Creativity
- Organizational capabilities
- Costly to imitate?
- Organized properly?